Skip to content

The Impact of Addition of Curcumin for 10 Days Triple Therapy, on the Eradication Rate of Helicobacter Pylori Infection

The Impact of Addition of Curcumin for 10 Days Triple Therapy, on the Eradication Rate of Helicobacter Pylori Infection

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02018328
Acronym
CurHP
Enrollment
150
Registered
2013-12-23
Start date
2014-01-31
Completion date
Unknown
Last updated
2014-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Positivity for Helicobacter Pylori

Brief summary

Background and Aims * H.pylori is a common human pathogen by which almost 50% of the world population is infected. According to the accepted guidelines, once H.pylori infection has been diagnosed,first line therapy with three drugs should be given. The triple treatment includes proton-pump-inhibitor-clarithromycin-amoxicillin but its eradication rate is only 70-80%. * Curcumin has many beneficial merits and it was also been demonstrated to be efficient in inhibition of H.pylori infection, in vitro.Therefore we aim to investigate whether addition of Curcumin to the standard triple therapy will increase the eradication rate of H.pylori infection. Methods * 150 consecutive patients that will undergo esophagogastroscopy in our Gastroenterology department and will be positive for H.pylori according to urease test and then by gastric biopsy, will be included. The patients will be randomized to two different treatments, according to binomial distribution. 75 patients will be treated with the standard triple therapy for 10 days and the other 75, will be treated for 10 days, with triple therapy combined with Curcumin that will be given three times a day. * During the treatment the patients will complete an adverse effect's questionnaires. 6 weeks after the completion of the treatment the patients will undergo urea breath test to confirm eradication. Patients will be asked to avoid antibiotics, bismuth compounds or proton-pump-inhibitor until the second urea-breath-test. * We will compare the eradication rate and the adverse effects between the two groups by using SPSS

Interventions

DIETARY_SUPPLEMENTCurcumin

Sponsors

Gingold Belfer Rachel
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* positivity for Helicobacter pylori by urease test and gastric biopsy

Exclusion criteria

* prior treatment for H. pylori * allergy to penicillin * gastric outlet obstruction * pregnancy or breast feeding * inability to understand the informed consent

Design outcomes

Primary

MeasureTime frame
Urea breath test6 weeks after the completion of the treatment

Countries

Israel

Contacts

Primary ContactRachel Gingold belfer, MD
RahelGB@clalit.org.il

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026